LFG
PCVX icon

Larson Financial Group’s Vaxcyte PCVX Stock Holding History

Larson Financial Group’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.46K Sell
94
-1
-1% -$54 ﹤0.01% 2733
2026
Q1 		$5.52K Sell
95
-151
-61% -$8.2K ﹤0.01% 2555
2025
Q4 		$11.3K Buy
246
+154
+167% +$6.89K ﹤0.01% 2041
2025
Q3 		$3.31K Buy
+92
New +$3.05K ﹤0.01% 2512
2025
Q2 		– Sell
-14
Closed -$529 – 3448
2025
Q1 		$529 Buy
+14
New +$1.12K ﹤0.01% 2562

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Larson Financial Group's PCVX Position: Q2 2026 in Review

Larson Financial Group reduced its Vaxcyte (PCVX) stake by 1.1% in Q2 2026, selling an estimated $54 and leaving 94 shares worth $5.46K. The position accounts for ﹤0.01% of the portfolio, ranked #2733.

Larson Financial Group first reported a position in PCVX in Q1 2025 and has held it in 5 quarters since. The position peaked at $11.3K in Q4 2025. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Larson Financial Group held 94 shares of Vaxcyte worth $5.46K as of Q2 2026.
  • Larson Financial Group sold 1 Vaxcyte share in Q2 2026, an estimated $54.
  • Vaxcyte made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #2733 holding.
  • Larson Financial Group first reported a position in Vaxcyte in Q1 2025 and has held it in 5 quarters since.
  • Larson Financial Group's Vaxcyte position peaked at $11.3K in Q4 2025.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.